Researchers Develop Blood Test Sensor for Early Alzheimer’s and Parkinson’s Detection
The sensor identifies misfolded protein biomarkers in blood before clinical symptoms of neurodegeneration appear.
Read MorePosted by CLP Edit Staff | May 26, 2026 | Dementias & Alzheimer’s, Diagnostic Technologies |
The sensor identifies misfolded protein biomarkers in blood before clinical symptoms of neurodegeneration appear.
Read MorePosted by CLP Edit Staff | May 19, 2026 | Amplification Technologies, Dementias & Alzheimer’s, Molecular Diagnostics |
Researchers at Mass General Brigham have developed a digital seed amplification assay that detects TDP-43 protein seeds in cerebrospinal fluid, enabling identification of FTLD-TDP, a specific frontotemporal lobar degeneration subtype.
Read MorePosted by CLP Edit Staff | May 12, 2026 | Company News, Dementias & Alzheimer’s, Diagnostic Technologies |
NeuroVision Imaging has acquired Durin Life Sciences, combining blood-based biomarker tests with retinal imaging and telehealth to advance early detection of Alzheimer’s and Parkinson’s diseases.
Read MorePosted by CLP Edit Staff | Apr 30, 2026 | Dementias & Alzheimer’s, Diagnostic Technologies, Immunoassay |
Research shows the pTau217 biomarker can identify risk for cognitive decline and amyloid buildup before changes appear on brain scans.
Read MorePosted by CLP Edit Staff | Apr 29, 2026 | Company News, Dementias & Alzheimer’s, Molecular Diagnostics |
Circular Genomics and Vitazi.ai have formed a partnership to combine AI-driven retinal imaging and blood-based RNA biomarkers for early Alzheimer’s disease detection, aiming to address gaps in early-stage patient identification.
Read More